Suchita P. Nety

Suchita P. Nety

Auto-generated profile, based on publicly available information

Suchita P. Nety

Howard Hughes Medical Institute, Cambridge, Massachusetts, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2021 in Science
Verified
Journal Article
Closed access
HAHan Altae-Tran
Han Altae-Tran
SKSoumya Kannan
Soumya Kannan
FDF. Esra Demircioglu
F. Esra Demircioglu
RORachel Oshiro
Rachel Oshiro
SNSuchita P. Nety
Suchita P. Nety
FZFeng Zhang
Feng Zhang
Tracing the origin of CRISPR-Cas: CRISPR-Cas systems have transformed genome editing and other biotechnologies; however, the broader origins and diversity of RNA-guided nucleases have largely remained unexplored. Altae-Tran et al . show that three distinct transposon-encoded proteins, IscB, IsrB, and TnpB, are naturally occurring, reprogrammable RNA-guided DNA nucleases (see the Perspective by Rousset and Sorek). In addition to identifying diverse guide-encoding mechanisms, the authors elucidate the evolutionary relationship between IsrB, IscB, and CRISPR-Cas9. Overall, these newly characterized systems, called OMEGA (for obligate mobile element–guided activity) systems, are found in all domains of life and may be harnessed for biotechnology development. —DJ

4 January 2018 in Nature
Verified
Journal Article
Closed access
PDF file
RBRaymond W. Bourdeau
Raymond W. Bourdeau
ALAudrey Lee-Gosselin
Audrey Lee-Gosselin
ALAnupama Lakshmanan
Anupama Lakshmanan
AFArash Farhadi
Arash Farhadi
SKSripriya Ravindra Kumar
Sripriya Ravindra Kumar
MSMikhail G. Shapiro
Mikhail G. Shapiro

7 September 2017 in Nature Protocols
Verified
Journal Article
Closed access
PDF file
ALAnupama Lakshmanan
Anupama Lakshmanan
GLGeorge J Lu
George J Lu
AFArash Farhadi
Arash Farhadi
SNSuchita P Nety
Suchita P Nety
MKMartin Kunth
Martin Kunth
MSMikhail G Shapiro
Mikhail G Shapiro

28 June 2016 in ACS Nano
Verified
Journal Article
Closed access
ALAnupama Lakshmanan
Anupama Lakshmanan
AFArash Farhadi
Arash Farhadi
SNSuchita P. Nety
Suchita P. Nety
ALAudrey Lee-Gosselin
Audrey Lee-Gosselin
RBRaymond W. Bourdeau
Raymond W. Bourdeau
MSMikhail G. Shapiro
Mikhail G. Shapiro

13 July 2020 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
ALAnupama Lakshmanan
Anupama Lakshmanan
ZJZhiyang Jin
Zhiyang Jin
SNSuchita P. Nety
Suchita P. Nety
DSDaniel P. Sawyer
Daniel P. Sawyer
ALAudrey Lee-Gosselin
Audrey Lee-Gosselin
MSMikhail G. Shapiro
Mikhail G. Shapiro

25 March 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
JJJulia Joung
Julia Joung
PKPaul C. Kirchgatterer
Paul C. Kirchgatterer
ASAnkita Singh
Ankita Singh
JCJang H. Cho
Jang H. Cho
SNSuchita P. Nety
Suchita P. Nety
FZFeng Zhang
Feng Zhang
The cellular processes that govern tumor resistance to immunotherapy remain poorly understood. To gain insight into these processes, here we perform a genome-scale CRISPR activation screen for genes that enable human melanoma cells to evade cytotoxic T cell killing. Overexpression of four top candidate genes (CD274 (PD-L1), MCL1, JUNB, and B3GNT2) conferred resistance in diverse cancer cell types and mouse xenografts. By investigating the resistance mechanisms, we find that MCL1 and JUNB modulate the mitochondrial apoptosis pathway. JUNB encodes a transcription factor that downregulates FasL and TRAIL receptors, upregulates the MCL1 relative BCL2A1, and activates the NF-κB pathway. B3GNT2 encodes a poly-N-acetyllactosamine synthase that targets >10 ligands and receptors to disrupt interactions between tumor and T cells and reduce T cell activation. Inhibition of candidate genes sensitized tumor models to T cell cytotoxicity. Our results demonstrate that systematic gain-of-function screening can elucidate resistance pathways and identify potential targets for cancer immunotherapy.